

Contents

Financial highlights	
■ Consolidated financial summary	2
■ Consolidated statement of financial position summary	2
■ Consolidated financial indices	2
■ Exchange rates	2
Consolidated information (5 years)	
Consolidated statements of income	3
Revenue details	4
■ Revenue by business segment	4
■ Revenue by region (Overseas)	4
■ Profit contribution by region (Based on new classification)	5
■ Profit contribution by region (Based on previous classification)	5
■ Revenue of major products	6
Consolidated statement of financial position	7
■ Assets	7
■ Equity and liabilities	7
Consolidated statements of cash flows	8
Other consolidated information	9
■ R&D expenses	9
■ Capital expenditures	9
■ Depreciation and amortization	9
■ Amortization on intangible assets associated with products	9
■ Additional detail of statement of financial position	9
■ Number of employees	9
Quarterly consolidated information	
Quarterly consolidated statements of income	10
Quarterly revenue details	11
■ Revenue by business segment	11
■ Revenue by region (Overseas)	11
■ Profit contribution by region (Based on new classification)	11
■ Revenue of major products	12
Reference information	
Pharmaceutical market in Japan	13
■ Revision of National Health Insurance (NHI) drug prices	13
■ Market shares by therapeutic area - prescription ophthalmics	13

1. Santen Group has adopted International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2015, for the purpose of enhancing the international comparability of its financial information.
2. The earnings forecasts and other forward-looking statements contained in this report are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual results may differ from these forecasts due to various factors.
3. Related to the acquisition of Eyeavance Pharmaceuticals Holdings Inc. (U.S.), as a result of the completion of the purchase price allocation in the six months ended September 30, 2021, the provisional figures used previously have been retroactively restated for the fiscal year ended March 31, 2021 and the first and second quarter of the fiscal year ended March 31, 2022.